At the Goldman Sachs 47th Annual Global Healthcare Conference held on June 8, 2026, Rhythm Pharmaceuticals, Inc. CEO David Meeker discussed the company's upcoming presentation of data related to Prader-Willi syndrome. Meeker expressed excitement about sharing results from a six-month open-label study conducted with 17 patients, which will include detailed metrics on weight change, Body Mass Index (BMI), and DEXA scan results that assess fat and lean body mass. Additionally, the study will feature two patient-reported outcomes: the HQ-CT, which measures health-related quality of life, and the PADQ questionnaire, aimed at assessing anxiety and distress levels. This comprehensive data presentation is set to provide stakeholders with a full picture of the study's findings, enhancing understanding of the treatment's impact on patients. The event precedes the ENDO conference, where further insights will be shared.